Last updated: February 21, 2026
What is the Drug Under NDC 69292-0580?
NDC 69292-0580 corresponds to Sage Therapeutics' zuranolone (brand name Ztalmy). Ztalmy is an oral therapy approved by the FDA in May 2023 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in pediatric patients aged 1 month to 17 years. It is a GABA_A receptor positive allosteric modulator.
Market Size and Therapeutic Context
Indications and Patient Population
Zuranolone is approved specifically for CDD, a rare genetic disorder with an estimated prevalence of approximately 1 in 40,000 live births worldwide. The total addressable market (TAM) involves:
- Patients aged 1 month to 17 years with CDD: Estimated at 10,000-15,000 globally.
- Market scope: Limited due to rarity; primarily driven by pediatric neurology and rare disease pharma channels.
Competitive Landscape
At present, no approved targeted therapies for CDD. Symptomatic treatments, mainly anticonvulsants (e.g., levetiracetam, clobazam), are used to manage seizures but lack disease-modifying effects.
Development Pipeline and Future Opportunities
Potential expansion to other seizure disorders and neurodevelopmental conditions linked to GABAergic deficits exists but remains speculative. No immediate pipeline competitors focus specifically on CDD.
Pricing Strategy and Reimbursement Dynamics
Current Pricing and Cost Estimates
-
List Price: The wholesale acquisition cost (WAC) for Ztalmy is approximately $36,000 per year based on initial pricing disclosures (research sources, May 2023).
-
Pricing Compared to Other Rare Disease Drugs:
- Epidiolex (cannabidiol) for rare syndromes: ~$32,500/year.
- Vimizim (elosulfase alfa): ~$380,000/year but for ultra-rare indication.
Reimbursement Challenges
Reimbursement largely hinges on:
- FDA approval for a rare pediatric condition.
- Payer willingness to fund high-cost therapies based on limited patient numbers.
- Use of patient assistance programs to offset costs in practice.
Price Projections and Market Trends
- Short-term: Prices likely to be stable at launch, around $36,000 annually.
- Medium-term: Possible discounts or rebates for payers once formulary inclusion occurs, potentially reducing net prices by 20-30%.
- Long-term: Price erosion is unlikely, given the scarcity and specialized niche. However, expansion to broader epilepsy indications could pressure prices downward.
Revenue Projections
Assumptions
- Initial annual sales: 1,000-2,000 patients treated, based on prevalence estimates.
- Market penetration: 50-70% within the first 3 years, considering clinician adoption and payer support.
- Price point stabilization at $36,000 per patient per year.
Revenue Estimate Scenarios
| Scenario |
Patients Treated |
Price per Patient |
Estimated Revenue (Year 1) |
| Conservative |
1,000 |
$36,000 |
$36 million |
| Moderate |
1,500 |
$36,000 |
$54 million |
| Optimistic |
2,000 |
$36,000 |
$72 million |
Note: These figures do not account for discounting, rebates, or rebates from pharmacy benefit managers (PBMs).
Regulatory and Market Risks
- The narrow indication limits market size.
- Fast adoption depends on clinician awareness and evidence generation.
- Potential for off-label use expansion could alter market dynamics.
- Pricing pressures from payers and legislative reforms affecting high-cost therapies.
Summary
NDC 69292-0580 (Ztalmy) operates in a niche, orphan drug market for CDD. The drug’s initial launch price approximates $36,000 annually, with revenue projections sensitive to patient uptake and reimbursement negotiations. While sales could grow modestly within the first few years, market limitations are significant due to the low prevalence of CDD.
Key Takeaways
- Ztalmy targets a rare, pediatric neurological disorder, limiting its total addressable market.
- Initial pricing is around $36,000 per year, comparable to similar niche epilepsy medications.
- Revenue depends heavily on market penetration, clinician acceptance, and payer reimbursement.
- Long-term price stability is expected due to the rarity and limited competition.
- Expansion into other seizure or neurodevelopmental indications could increase market size.
Frequently Asked Questions
Q1: Will the price of Ztalmy decrease over time?
A1: Price reductions are unlikely unless competition emerges or if payers negotiate significant rebates.
Q2: How does the rarity of CDD influence market potential?
A2: It confines market potential to approximately 10,000-15,000 patients globally, limiting large-scale revenue opportunities.
Q3: Are there any approved competing drugs for CDD?
A3: No. Ztalmy is the first FDA-approved therapy specifically for CDD-related seizures.
Q4: Could expansion to other indications affect pricing?
A4: If Ztalmy gains approval for broader epilepsy or neurodevelopmental disorders, revenues could increase, but pricing pressure may follow.
Q5: What factors influence reimbursement for Ztalmy?
A5: FDA approval for a rare pediatric indication, clinical effectiveness, payer policies on orphan drugs, and patient access programs.
References
- FDA. (2023). Ztalmy (zuranolone) approval announcement.
- IQVIA. (2023). Annual drug pricing and market data.
- Evaluate Pharma. (2023). Rare disease drug market forecasts.
- IQVIA. (2023). Payer policy reports on orphan drugs.
- Orphan Drug Designations and Approvals. (2023). FDA database.
[1] Food and Drug Administration. (2023). Ztalmy (zuranolone). FDA.
